Efficacy of @entity4381 in treatment of @entity170 in @entity1 and XXXX -a meta-analysis.

@entity1 @entity5921 @entity171 @entity174 @entity170 @entity79 @entity173 @entity4381
BACKGROUND: @entity170 is a significant cause of morbidity and mortality in the elderly and an important public health issue. @entity171 are the primary treatment options for @entity170 . The oral administration of @entity171 may result in poor @entity1 compliance and thence reduced treatment efficacy. Intravenously administered @entity171 may therefore show better treatment efficacy. We have carried out a meta-analysis to evaluate the efficacy of @entity4381 treatment for @entity170 in both @entity1 and @entity1 with either @entity174 . MATERIAL AND METHODS: Randomized controlled trials with @entity4381 treatment for @entity170 were retrieved from PubMed, EMBASE and clinicaltrials.gov. The risk ratio with 95% confidence interval (RR, 95% CI) was calculated to evaluate the effect of @entity4381 treatment on incidence of @entity174 . Data on changes in @entity79 ( @entity79 ) following @entity4381 ( @entity5921 ) treatment was also extracted. STATA software was used for all the statistical analyses. RESULTS: Significant reduction in the incidence of both vertebral and nonvertebral @entity174 was observed following @entity5921 treatment, as seen from the values for RR with 95% CI (RR 0.24 and 95% CI 0.15 to 0.40 for @entity174 ; RR 0.76 and 95% CI 0.67 to 0.86 for @entity174 ). @entity79 was also seen to be increased after @entity5921 treatment. CONCLUSION: Ourmeta-analysis showed that @entity4381 was effective in reducing the incidence of @entity174 as well as @entity174 , including @entity173 . Significant increase in @entity79 ( @entity79 ) was also observed in @entity1 administered @entity5921 as compared to placebo.
